Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
Open Access
- 9 August 2019
- journal article
- review article
- Published by Wiley in HemaSphere
- Vol. 3 (5), e287
- https://doi.org/10.1097/hs9.0000000000000287
Abstract
The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progression-free survival and more frequently observed deep remissions there is an emerging need for sensitive methods quantitating residual disease after therapy. Over the last decade, assessment of minimal residual disease (MRD) has increasingly been implemented in CLL trials. The predictive value of MRD status on survival outcomes has repeatedly been proven in the context of chemoimmunotherapy and cellular therapies. Recent data suggests a similar correlation for Bcl-2 inhibitor-based therapy. While the relevance of MRD assessment as a surrogate endpoint in clinical trials is largely undisputed, its role in routine clinical practice has not yet been well defined. This review outlines current methods of MRD detection in CLL and summarizes MRD data from relevant trials. The significance of MRD testing in clinical studies and in routine patient care is assessed and new MRD-guided treatment strategies are discussed.Funding Information
- AbbVie
- Gilead Sciences
- Roche
This publication has 92 references indexed in Scilit:
- Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemiaLeukemia, 2013
- High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessmentProceedings of the National Academy of Sciences of the United States of America, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysisLeukemia, 2009
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- Skin lesions in chronic lymphocytic leukemiaLeukemia & Lymphoma, 2007
- Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood, 2005
- Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantationLeukemia, 2004
- Hypercalcaemia and osteolytic bone lesions in chronic lymphocytic leukaemia.BMJ, 1980